← Leaderboards
Brent Kuenzi
University Of South Florida
$310,369
Attributed
$310,369
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $87.6K · FY2016–20$100K$75K$50K$25K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$310,369 · 2
By mechanism
K00$240,689 · 1
F99$69,680 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of South Florida
Same institution · by research overlap
- Yuri Jang$4,436,980
- Mack H Wu$7,583,499
- Jie Wu$6,950,728
- Qing Ping Dou$2,687,424
- Warren Jackson Pledger$8,054,101
Others in their field
Top investigators on “Generations”
- Richard A Gibbs · Baylor College Of Medicine$539,942,150
- David Heimbrook · Leidos Biomedical Research, Inc.$461,253,475
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- Dennis R. Burton · Scripps Research Institute$280,469,869
- Eric S Lander · Whitehead Institute For Biomedical Res$262,517,055
Research focus
GenerationsAnaplastic Lymphoma KinaseEffective TherapyFda ApprovedAwardBaseAnticancer ActivityDrug UsageBiomarker DevelopmentDrug TargetingCancer Cell LineCancer PatientCareerCell SurvivalChimeric ProteinsBioinformaticsCombined Modality TherapyBiologyData SetDesignCancer CellAnticancer ResearchDrug CandidateGene Silencing
Grant awards (5)
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer$87,577
K00 · FY2020 · CA · contact PI
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer$83,290
K00 · FY2019 · CA · contact PI
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer$69,822
K00 · FY2018 · CA · contact PI
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer$34,324
F99 · FY2017 · CA · contact PI
New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer$35,356
F99 · FY2016 · CA · contact PI